Repligen Corporation has received a $1 million milestone payment from Pfizer under the companies’ exclusive development agreement for spinal muscular atrophy (SMA) compounds. The milestone was triggered by the conclusion of specific program activities and the successful completion of all of Repligen’s transition obligations. Repligen remains eligible to receive as much as $64 million in success-based milestones and royalties on sales.   “Consistent with our strategic decision last Au...